VacciMax® Vaccine Eradicates Large HPV-16 Tumors in Aged Mice
Author Information
Author(s): Daftarian Pirouz M, Mansour Marc, Pohajdak Bill, Fuentes-Ortega Antar, Korets-Smith Ella, MacDonald Lisa, Weir Genevieve, Brown Robert G, Kast W Martin
Primary Institution: ImmunoVaccine Technologies Inc.
Hypothesis
Can a novel vaccine delivery platform effectively reject large established tumors in aged mice?
Conclusion
The study found that a single immunization with a VacciMax®-formulated vaccine eradicated large tumors in aged mice within three weeks.
Supporting Evidence
- Vaccination with the four-peptide mixture eradicated tumors in all treated mice.
- None of the vaccinated mice developed tumors upon re-challenge with a different tumor cell line.
- The vaccine was administered as a single dose and showed rapid efficacy.
- Peptide-specific immune responses were confirmed through ELISPOT assays.
Takeaway
Researchers created a special vaccine that helped older mice get rid of big tumors quickly, showing it could be a good way to fight cancer.
Methodology
The study used HLA-A2 transgenic mice of advanced age and tested various formulations of a vaccine containing HPV peptides.
Potential Biases
Potential bias in the selection of tumor models and the interpretation of immune response data.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
HLA-A2 transgenic mice aged 48–58 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website